Functional analysis of allergen-specific IgG4 in transcutaneous sensitization and desensitization

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K17768
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 53050:Dermatology-related
• Research Institution: Nagoya University
• Principal Investigator: Ogawa-Momohara Mariko 名古屋大学, 医学部附属病院, 助教 (50835741)
• Project Period (FY): 2021-11-01 – 2024-03-31
• Keywords: アレルゲン / IgE / IgG4

Outline of Final Research Achievements

We conducted a prospective study in patients with atopic dermatitis (AD) to investigate whether allergen-specific IgG4 (sIgG4) is reduced by B cell suppression due to the therapeutic effect of the anti-IL4/IL13 receptor monoclonal antibody dupilumab. As a result of the investigation, dupilumab treatment suppressed the production of IgE and IgG, but only allergen-specific IgG4 (neutralizing antibody) showed a tendency to increase. It has been shown that dupilumab may reduce the response to allergens by suppressing IgE production and increasing IgG4 production.

Free Research Field

アトピー性皮膚炎

Academic Significance and Societal Importance of the Research Achievements

近年アトピー性皮膚炎に対するバイオ製剤や低分子化合物が多数使用可能になってきている。デュピルマブの持つ今まで知られていなかった新たな作用機序による治療効果の可能性を示し、今後各患者に至適の医療を提供するために重要な薬剤の特性に関する理解を深める一助となった。